Chen Hsin-Hung, Horng Ming-Hwarng, Yeh Su-Yin, Lin I-Ching, Yeh Chih-Jung, Muo Chih-Hsin, Sung Fung-Chang, Kao Chia-Hung
School of Public Health, Chung Shan Medical University, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan; Division of Metabolism & Endocrinology, Changhua Christian Hospital, Changhua, Taiwan; Division of Metabolism & Endocrinology, Nantou Christian Hospital, Nantou, Taiwan.
Division of Critical Care Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; Changhua Christian medical foundation, Yuanlin Christian Hospital, Changhua, Taiwan.
PLoS One. 2015 Aug 28;10(8):e0135530. doi: 10.1371/journal.pone.0135530. eCollection 2015.
Diabetes is a common diseases and a major problem worldwide. Diabetic osteopathy might be elevated in diabetic patients and is usually caused by bone fracture. Several diabetes medications, such as thiazolidinediones (TZDs), could lead to increased risks of fracture.
We used the nationwide database to identified 32466 patients who had developed type 2 diabetes from 2000 to 2010 as the diabetic cohort and, from that group, we selected 3427 diabetic patients who had developed bone fracture to survey the possible risk factors, includng commonly used diabetes medication.
We found that TZDs might present increased risks for fracture in patients who used it for an extended period (7 to 730 days before the index date), especially in female patients younger than 64 years old, for whom the risk was elevated from a 1.74- to a 2.58-fold odds ratio.
We recommend that clinics follow up with non-osteoporotic female patients younger than 64 years old who are using TZDs, to avoid the associated risks of fracture.
糖尿病是一种常见疾病，也是全球范围内的一个主要问题。糖尿病性骨病在糖尿病患者中可能会增加，通常由骨折引起。几种糖尿病药物，如噻唑烷二酮类（TZDs），可能会导致骨折风险增加。
我们使用全国性数据库，确定了2000年至2010年期间患2型糖尿病的32466名患者作为糖尿病队列，从该组中选取3427名发生骨折的糖尿病患者，以调查可能的风险因素，包括常用的糖尿病药物。
我们发现，TZDs可能会使长期使用（索引日期前7至730天）的患者骨折风险增加，尤其是64岁以下的女性患者，其风险从1.74倍增加到2.58倍的优势比。
我们建议临床对使用TZDs的64岁以下非骨质疏松女性患者进行随访，以避免相关的骨折风险。
